Clinical data and results of immunohistologic and molecular studies
| Patient . | Sex/age (y) . | Site (solitary/ clustered/multiple lesions) . | κ/λ . | JH-PCR (entire specimen) . | MD-PCR Follicles . | MD-PCR IF . | Therapy (response) . | Follow-up (mo) . |
|---|---|---|---|---|---|---|---|---|
| 1 | M/35 | Cheek, arm (MU) | − | M | M | P′ | SE (CR); recurrence | A&D (31) |
| 2 | F/53 | Forehead (CL) | − | P | P | P | Rx (CR) | A&W (39) |
| 3 | F/52 | Forehead (SO) | − | P | P | P | SE (CR); recurrence | A&D (21) |
| 4 | M/60 | Forehead (CL) | − | P | P | P | SE (CR); recurrence: Rx (CR) | A&W (38) |
| 5 | M/62 | Scalp (SO) | − | M | M | P′ | Rx (CR); recurrence | A&D (13) |
| 6 | F/48 | Scalp, arms (MU) | +κ | P | P | P | Rx (CR); recurrence: Rx (CR) | A&W (95) |
| 7 | F/42 | Shoulders (MU) | − | M | ND | ND | SE (CR) | A&W (14) |
| 8 | F/56 | Breast (SO) | − | P | P | P | SE + Rx (CR) | A&W (63) |
| 9 | F/75 | Abdomen (CL) | − | M | M | P′ | Rx (CR) | A&W (11) |
| 10 | F/64 | Forehead (CL) | − | M | ND | ND | SE + Rx (CR) | A&W (65) |
| 11 | F/87 | Scalp (MU) | − | M | M | P′ | Rx (PR) | A&D (13) |
| 12 | F/52 | Arms (MU) | − | M | ND | ND | SE (CR); recurrence: SE + Rx (CR) | A&W (113) |
| 13 | M/24 | Scalp, cheek (MU) | − | M | M | P | Rx (CR); recurrence: Rx (CR) | A&W (79) |
| 14 | M/46 | Scalp (CL) | − | P | P | P | Rx (CR) | A&W (81) |
| 15 | F/41 | Breast (SO) | − | M | M | P | SE + Rx (CR); recurrence | A&D (54) |
| Patient . | Sex/age (y) . | Site (solitary/ clustered/multiple lesions) . | κ/λ . | JH-PCR (entire specimen) . | MD-PCR Follicles . | MD-PCR IF . | Therapy (response) . | Follow-up (mo) . |
|---|---|---|---|---|---|---|---|---|
| 1 | M/35 | Cheek, arm (MU) | − | M | M | P′ | SE (CR); recurrence | A&D (31) |
| 2 | F/53 | Forehead (CL) | − | P | P | P | Rx (CR) | A&W (39) |
| 3 | F/52 | Forehead (SO) | − | P | P | P | SE (CR); recurrence | A&D (21) |
| 4 | M/60 | Forehead (CL) | − | P | P | P | SE (CR); recurrence: Rx (CR) | A&W (38) |
| 5 | M/62 | Scalp (SO) | − | M | M | P′ | Rx (CR); recurrence | A&D (13) |
| 6 | F/48 | Scalp, arms (MU) | +κ | P | P | P | Rx (CR); recurrence: Rx (CR) | A&W (95) |
| 7 | F/42 | Shoulders (MU) | − | M | ND | ND | SE (CR) | A&W (14) |
| 8 | F/56 | Breast (SO) | − | P | P | P | SE + Rx (CR) | A&W (63) |
| 9 | F/75 | Abdomen (CL) | − | M | M | P′ | Rx (CR) | A&W (11) |
| 10 | F/64 | Forehead (CL) | − | M | ND | ND | SE + Rx (CR) | A&W (65) |
| 11 | F/87 | Scalp (MU) | − | M | M | P′ | Rx (PR) | A&D (13) |
| 12 | F/52 | Arms (MU) | − | M | ND | ND | SE (CR); recurrence: SE + Rx (CR) | A&W (113) |
| 13 | M/24 | Scalp, cheek (MU) | − | M | M | P | Rx (CR); recurrence: Rx (CR) | A&W (79) |
| 14 | M/46 | Scalp (CL) | − | P | P | P | Rx (CR) | A&W (81) |
| 15 | F/41 | Breast (SO) | − | M | M | P | SE + Rx (CR); recurrence | A&D (54) |
CL, clustered lesions; MU, multiple lesions; SO, solitary lesions; κλ, immunohistochemical analysis of immunoglobulin light chain expression; MD-PCR follicles, microdissection-based PCR analysis of JH genes in follicles; MD-PCR IF, microdissection-based PCR analysis of JH genes in interfollicular areas; M, monoclonal pattern; P, polyclonal pattern; P′, polyclonal pattern with 1 or more interfollicular lanes showing a band at the same length as that observed within follicles; ND, not done; Rx, radiotherapy; SE, surgical excision; CR, complete response; PR, partial response; A&D, alive with skin disease; A&W, alive and well.